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Abstract
Papillon–Lefevre syndrome (PLS; OMIM 245000) is an autosomal recessive
condition characterized by palmoplantar hyperkeratosis and periodontitis. In
1997, the gene locus for PLS was mapped to 11q14-21, and in 1999, variants in
the cathepsin C gene (CTSC) were identified as causing PLS. To date, a total of
75 different disease-causing mutations have been published for the CTSC gene.
A summary of recurrent mutations identified in Hungarian patients and a
review of published mutations is presented in this update. Comparison of clini-
cal features in affected families with the same mutation strongly confirm that
identical mutations of the CTSC gene can give rise to multiple different pheno-
types, making genotype–phenotype correlations difficult. Variable expression of
the phenotype associated with the same CTSC mutation may reflect the influ-
ence of other genetic and/or environmental factors. Most mutations are mis-
sense (53%), nonsense (23%), or frameshift (17%); however, in-frame
deletions, one splicing variant, and one 5′ untranslated region (UTR) mutation
have also been reported. The majority of the mutations are located in exons 5–
7, which encodes the heavy chain of the cathepsin C protein, suggesting that
tetramerization is important for cathepsin C enzymatic activity. All the data
reviewed here have been submitted to the CTSC base, a mutation registry for
PLS at http://bioinf.uta.fi/CTSCbase/.
Background
Papillon–Lefevre syndrome (PLS; OMIM 245000) is a rare
form of palmoplantar keratodermas. It was first described
by Papillon and Lefevre (1924). The main characteristic
features of PLS are symmetrical palmoplantar hyperkera-
tosis and periodontal inflammation, causing loss of both
the primary and permanent teeth.
Keratoderma in PLS can present in the first 3 months
of life, although palmoplantar hyperkeratosis generally
first appears in years 1–4 (Haneke 1979). However, sev-
eral late-onset variants of PLS have also been reported
(Bullon et al. 1993; Pilger et al. 2003). Skin symptoms
include transgrediens spread with hyperkeratosis of palms
and soles. Diffuse hyperkeratosis is the most commonly
observed type; however, the punctuate type occurs rarely.
Generally, hyperkeratosis in PLS is not severe (Toomes
et al. 1999). Psoriasiform lesions may also develop on the
elbows, knees, and knuckles (Toomes et al. 1999). As PLS
skin lesions are similar to Mal de Meleda (OMIM
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248300) lesions, another rare form of palmoplantar kera-
todermas, PLS was first considered as a variant of Mal de
Meleda. Subsequently, it was determined that the two dis-
eases are different forms of palmoplantar keratodermas
(Gorlin et al. 1964).
Periodontitis and gingivitis result in the loss of primary
and permanent teeth (Gorlin et al. 1964; Toomes et al.
1999; Hart et al. 2000c; Hewitt et al. 2004a,b). As symp-
toms appear as the teeth erupt, PLS patients typically
report two episodes of gingivitis: the first one at ~3 years
of age, leading to the loss of primary teeth (Lundgren and
Renvert 2004), the second one at ~15 years of age, result-
ing in the loss of permanent teeth (Fardal et al. 1998).
In addition to these symptoms, recurrent skin infec-
tions and liver abscesses are frequently reported (de Haar
et al. 2004; Pham et al. 2004a,b; Romero-Quintana et al.
2013). Moreover, mild mental retardation, intracranial
calcifications, and hyperhidrosis can also occur (Haneke
1979). Japanese patients might have an increased risk of
developing melanomas at the sites of hyperkeratosis (Nak-
ajima et al. 2008) than other ethnic groups. The preva-
lence of the disease is 1–4 cases per million and more
than 300 cases have been reported worldwide (Gorlin
et al. 1964; Haneke 1979). PLS has been reported to
occur in a diverse range of ethnic groups and parental
consanguinity has been noted in more than 50% of the
cases (Gorlin et al. 1964).
PLS is transmitted as an autosomal recessive condition
affecting males and females equally. PLS was indepen-
dently mapped to chromosome 11q14-21 by three groups
(Fischer et al. 1997; Laass et al. 1997; Hart et al. 1998).
In the mapped region, the causative cathepsin C gene
(CTSC) was independently identified by two groups (Hart
et al. 1999; Toomes et al. 1999). The CTSC, GenBank
accession number NM_001814.4 spans over 46 kb and
contains seven exons and six introns (Toomes et al.
1999). According to the Ensemble genome browser
(http://www.ensembl.org), this gene has nine splice vari-
ants. Of these, five occur in protein coding regions; the
remaining four are noncoding transcripts.
CTSC encodes the cathepsin C protein (dipeptidyl-pep-
tidase I), a lysosomal exo-cysteine proteinase belonging to
the peptidase C1 family. Cathepsin C is an oligomeric
enzyme composed of four identical subunits (Dolenc
et al. 1995; Paris et al. 1995). Each subunit contains three
different polypeptides – heavy, light, and propeptide
chains – which are held together by noncovalent interac-
tions (Cigic et al. 1998). The C-terminus of the propep-
tide is cleaved upon activation. The residual propeptide is
cleaved into two peptides, which are held together by a
disulfide bond (Cigic et al. 1998).
Cathepsin C has the ability to remove dipeptides from
the amino terminus of proteins and is involved in the
zymogen activation of serine proteases. This activity was
proposed to play a role in epithelial differentiation and
desquamation (Toomes et al. 1999).
In 1999, the first eight mutations of the CTSC gene
were identified in consanguineous PLS families (Toomes
et al. 1999). Since 1999, several reports have described
mutations in the CTSC gene in different PLS cases from
around the world (Table 1). CTSC mutations have also
been reported in patients with Haim–Munk syndrome
(HMS, OMIM 245010), also characterized by palmoplan-
tar hyperkeratosis and periodontal inflammation, as well
as arachnodactly, acroosteolysis, pesplanus, and onycho-
gryposis (Hart et al. 2000b). CTSC mutations were also
found in aggressive periodontitis (AP1, OMIM 170650),
which is characterized by severe periodontal inflammation
leading to tooth loss without the presence of skin symp-
toms (Hart et al. 2000c; Hewitt et al. 2004a,b).
To date, a total of 75 mutations have been reported for
the CTSC gene. The majority of the mutations (97%)
were reported in PLS cases, while only a few mutations
(3%) were reported in HMS or AP1 cases. Note that
some mutations were detected in two different disease
entities: c.1040A>G p.Tyr347Cys was reported for AP1
and also for classic PLS families (Toomes et al. 1999;
Hart et al. 2000c; Hewitt et al. 2004a,b), c.145C>T
p.Gln49X was reported for HMS and for PLS pedigrees
(Selvaraju et al. 2003; Rai et al. 2010) and c.857A>G
p.Gln286Arg was present in patients either with the HMS
or with the PLS phenotype (Hart et al. 2000b). Therefore,
PLS, HMS, and AP1 are not different entities; they repre-
sent the phenotypic spectrum of a single disease.
Database
A PubMed (http://www.ncbi.nlm.nih.gov/pubmed) litera-
ture search was performed to identify all known CTSC
mutations. In addition, Hungarian pedigrees with PLS
were screened for CTSC mutations and added to this arti-
cle. All available information about mutation carriers have
been uploaded to the CTSCbase, a mutation registry for
PLS (Piiril€a et al. 2006). This database is included in the
Human Genome Variation Society (HGVS) (www.HGVS.
org) list of locus-specific databases. The database can be
visited at http://bioinf.uta.fi/CTSCbase/ and has been
updated with data from the literature as well as unpub-
lished variants identified in Hungarian PLS pedigrees.
Summary of Clinical Findings for
Hungarian PLS Patients With
Recurrent Mutations
In Hungary, mutation screening for the CTSC gene has
been available since 2011. Screening is performed with
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direct sequencing of all coding regions and flanking in-
trons of the CTSC gene. Once a putative causative variant
was identified in a patient, the available, clinically symp-
tom-free family members and unrelated, healthy control
individuals were also investigated.
We have recently identified a Hungarian family with
two sisters affected with mild palmoplantar hyperkerato-
sis and severe periodontitis leading to the loss of all pri-
mary teeth. These patients carried the recurrent
c.566delCATACAT p.Thr189fsX199 frameshift mutation
in a homozygous form (Farkas et al. 2013). An unaf-
fected sister and the parents carried the same mutation
in a heterozygous form. The family was not aware of
consanguinity. This frameshift mutation has also been
previously published for two Moroccan PLS patients pre-
senting variation in the severity of the skin symptoms
(Noack et al. 2008a,b).
In another Hungarian family with two sisters present-
ing severe tooth loss and different degrees of palmoplan-
tar hyperkeratosis (severe and mild), the sisters were
found to carry the c.901G>Ap.Gly301Ser missense muta-
tion in a homozygous form (data not published). The
family was not aware of consanguinity. This mutation has
also been previously published for a German patient with
typical PLS skin symptoms (Noack et al. 2008a,b).
In a pair of unrelated Hungarian patients with typical
PLS phenotype (a 25-year-old male patient and a 39-
year-old female patient), we have identified the
c.748C>Tp.Arg250X homozygous nonsense mutation
(data not published). Unfortunately, both of these patients
were reared in state care and have no known relatives;
therefore, investigation of the family was not possible. The
fact that both individuals carry the same mutation
raises the possibility that these patients are relatives. This
Table 1. Summary of studies reporting CTSC gene mutations.
Location Mutation Ethnicity References
5′UTR c.-55C>A Slovenian Kosem et al. (2012)
Exon 1 c.21delG, c.72C>A, c.90C>A, c.96T>G,
c.113delCCTG, c.116G>C, c.145C>T
Chinese, French, Indian, Mexican,
Moroccan, North African, North
American, Puerto-Rican, Thai
Lefevre et al. (2001), Nakano et al. (2001), Zhang
et al. (2002), Allende et al. (2003), Selvaraju
et al. (2003), Hewitt et al. (2004a,b), Pham et al.
(2004a,b), Nitta et al. (2005), Yang et al. (2007),
Kurban et al. (2010)
Exon 2 c.199del24, c.203T>G, c.205C>T,
c.267delGG
Brazilian, Chinese, Indian, Mexican Hart et al. (2000a,b,c), Selvaraju et al. (2003),
Pallos et al. (2010), Romero-Quintana et al.
(2013)
Exon 3 c.322A>T, c.380A>C, c.386T>A,
c.415G>A, c.436delT, c.444insATGT,
c.458C>T
Chinese, Egyptian, French, German,
Indian, North American, Scotish,
Turkish
Hart et al. (2000a,b,c), Lefevre et al. (2001), Hewitt
et al. (2004a,b), Cagli et al. (2005), Yang et al.
(2007), Noack et al. (2008a,b), Kobayashi et al.
(2013)
Intron 3 c.485-1G>A Egyptian, Jordanian Toomes et al. (1999)
Exon 4 c.555G>A, c.566delCATACAT,
c.587T>C, c.622insC, c.628C>T,
c.629delGA
Algerian, Brazilian, German,
Hungarian, Indian, Iranian,
Lebanese, Moroccan, Russian,
Turkish,
Hart et al. (2000a,b,c, 2002), Cury et al. (2002),
Noack et al. (2004, 2008a,b), Cury et al. (2005),
Wani et al. (2006), Farkas et al. (2013)
Exon 5 c.704G>A, c.706G>T, c.711del14,
c.739A>C, c.745G>T, c.748C>T,
c.755A>T, c.756ins130
Algerian, Chinese, Egyptian, Eritrean,
Indian, Iranian, North American,
Pakistanian, Spanish, Turkish
Toomes et al. (1999), Hart et al. (2000a,b,c),
Allende et al. (2001), Lefevre et al. (2001), Hewitt
et al. (2004a,b), Jouary et al. (2008), Wen et al.
(2012)
Exon 6 c.778T>C, c.815G>A, c.815G>C,
c.851G>A, c.854C>T, c.856C>T,
c.857A>G, c.872G>A, c.880T>C
Belgian, Chinese, French, Holland,
Indian, Lebanese, Moroccan, North
American, Russian, Saudi, Spanish,
Sri Lankan, Turkish
Hart et al. (1999, 2000a,b,c), Toomes et al. (1999),
Allende et al. (2001, 2003), Lefevre et al. (2001),
Zhang et al. (2002), de Haar et al. (2004), Hewitt
et al. (2004a,b), Pham et al. (2004a,b), Yang
et al. (2007), Noack et al. (2008a,b)
Exon 7 c.890G>T, c.898G>A, c.899G>A,
c.901G>A, c.901G>T, c.902G>T,
c.910T>A, c.912C>A, c.923G>A,
c.935A>G, c.947T>G, c.956A>G,
c.984delTTCTCCA, c.1015C>T,
c.1019A>G, c.1028delCT, c.1040A>G,
c.1047delA, c.1056delT, c.1131T>G,
c.1141delC, c.1156G>C
Egyptian, French, German, Indian,
Indian–Pakistanian, Iranian,
Japanese, Jordanian, Martinique,
North American, Panamanian,
Saudi, Sri Lankan, Turkish,
Vietnamese
Hart et al. (1999, 2000a,b,c), Toomes et al. (1999),
Lefevre et al. (2001), Nakano et al. (2001), Zhang
et al. (2001), Selvaraju et al. (2003), de Haar
et al. (2004, 2005), Hewitt et al. (2004a,b),
Noack et al. (2004, 2008a,b), Wani et al. (2006),
Jouary et al. (2008), Castori et al. (2009), Wen
et al. (2012)
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mutation has also been previously published in the litera-
ture in a Turkish PLS family (Hart et al. 2000a).
Variants in the CTSC Gene
To date, a total of 75 mutations have been identified for
the CTSC gene, all of which are registered in the CTSC-
base. Mutations are named according to HGVS nomen-
clature guidelines (www.HGVS.org) and numbered with
respect to the CTSC gene reference sequence
(ENSG00000109861 corresponding to the CTSC gene
transcript ENST00000227266). The 75 unique mutations
– point mutations, small deletions, and insertions – are
summarized in Figure 1.
Of the reported 75 mutations, 53% are missense
(n = 40), 23% are nonsense (n = 17) and 17% are frame-
shift (n = 13) variants. There are two in-frame deletions,
one intronic splice-site variant and one point mutation in
the 5′ untranslated region (UTR) of the CTSC gene. The
majority (75%, n = 56) of the mutations has only been
reported once. Among these, 65% (n = 36) were present
in homozygous form in the investigated patients, while
35% (n = 20) occurred in a compound heterozygous
form. Recurrent mutations (25% of all mutations,
n = 19) occurred both in homozygous and in compound
heterozygous forms and were detected in geographically
distant, unrelated families, suggesting mutational cluster-
ing on the CTSC gene. However, there are reports sug-
gesting that an initial founder effect and subsequent
migration of carriers can lead to the presence of the same
mutation in geographically distant and unrelated families
(Zhang et al. 2001; Kurban et al. 2009).
Known mutations that have been sequenced are
unequally distributed on the CTSC gene. Half of the
mutations (53%, n = 41) are located within exons 5–7,
encoding amino acids 231–394 in the heavy-chain region.
Exon 3
c.322A>T 
c.380A>C 
c.386T>A 
c.415G>A
c.436delT
c.444insATGT
c.458C>T‡
Exon 6
c.778T>C 
c.815G>C 
c.815G>A
c.851G>A 
c.854 C>T
c.856C>T
c.857A>G# 
c.872G>A 
c.880T>C
Exon 4
c.555G>A 
c.566delCATACAT 
c.587T>C †
c.622insC
c.628C>T 
c.629delGA
c.681delCATACAT
ATG TAG
Translated exonic region
Untranslated exonic region
Exon 1
c.21delG
c.72C>A
c.90C>A 
c.96T>G 
c.113delCCTG
c.116G>C 
c.145C>T#
Exon 2
c.199delTACCTTCAGAAGCTGGATACAGCA
c.203T>G 
c.205C>T 
c.267delGG
Exon 5
c.704G>A 
c.706G>T 
c.711del14
c.739A>C 
c.745G>T
c.748C>T 
c.755A>T 
c.756ins130
Exon 7
c.890G>T
c.898G>A 
c.899G>A 
c.901G>A
c.901G>T 
c.902G>T 
c.910T>A
c.912C>A
c.923G>A 
c.935A>G 
c.947T>G 
c.956A>G 
c.984delTTCTCCA
c.1015C>T 
c.1019A>G
c.1028delCT  
c.1040A>G*
c.1047delA 
c.1056delT 
c.1131T>G
c.1141delC 
c.1156G>C
c.1213C>A 
c.1214A>G‡
c.1213delCAT
c.1235A>G‡
c.1268G>C
c.1269G>A 
c.1286G>A 
c.1287G>C
c.1340A>G
c.1357A>G‡
Intron 3
c.485-1G>A
5’UTR
c.-55C>A
# Reported in PLS and HMS
* Reported in PLS and AP1
† Detected in HMS only
‡ Polymorphism described as a causaƟve variant in PLS 
Figure 1. Schematic drawing of the CTSC gene, indicating the positions of mutations leading to PLS, HMS, and AP1. Identical mutations can
lead to different diseases. The involvement of mutations in specific diseases is indicated as follows: #, PLS and HMS; *, PLS and AP1; †, HMS; ‡,
common missense variants reported as causative for PLS.
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Of the remaining half, 16% (n = 12) are located within
exons 1–3 encoding amino acids 25–134 in the exclusion
domain, 12% (n = 9) are located within the second half
of exon 7 encoding amino acids 395–463 in the light-
chain region, 13% (n = 10) are located within exon 4 and
the first half of exon 5 encoding amino acids 135–230 in
the propeptide region, 3% (n = 2) are located in the 5′
end of exon 1 encoding amino acids 1–24 in the signal
peptide region and 3% (n = 2) are located within UTRs.
Note, not all mutations have been identified by DNA
sequencing.
Homozygous Mutations
To date, 68% of all identified CTSC mutations (n = 75)
were reported in a homozygous form in PLS patients. Of
these mutations, 85% (n = 64) were present only in
homozygous form in PLS patients, while 15% (n = 11)
were also detected in a compound heterozygous state.
Among the homozygous mutations, 50% (n = 32) were
missense, 25% (n = 16) nonsense, 23% (n = 15) frame-
shift mutations, and 2% (n = 1) were other types of
mutations (Fig. 2A).
Missense Variants
Missense mutations account for approximately half (53%,
n = 41) of all CTSC gene mutations identified to date.
Missense mutations occur in all coding regions of the
gene; however, the majority occurs in exons 5–7, encod-
ing the heavy-chain region of the cathepsin C protein
(Fig. 3A), which is thought to be important for enzyme
activity (Turk et al. 2001).
In addition to mutations of the CTSC gene, it is
important to note that some polymorphisms are com-
mon for this gene. For example, the c.458C>T
p.Thr153Ile missense variant, which corresponds to vari-
ant rs217086, occurs at a residue that is conserved in
mammals and is located in the portion of the propeptide
that is cleaved upon activation (Hart et al. 2000a). The
c.458C>T p.Thr153Ile polymorphism has been indenti-
fied in several PLS families, but does not have a causa-
tive role in the development of PLS (Allende et al. 2001;
Nakano et al. 2001; de Haar et al. 2004; Romero-Quin-
tana et al. 2013).
Further missense variants of the CTSC gene reported in
PLS families have also been detected as rare polymor-
phisms as well: c.1214A>Gp.His405Arg corresponds the
rs151269219 polymorphism (de Haar et al. 2005; Noack
et al. 2008a,b), c.1235A>Gp.Tyr412Cys to the rs28937571
(Hewitt et al. 2004a,b), and c.1357A>Gp.Ile453Val to the
rs3888798 polymorphism (Nakano et al. 2001). All of
these missense polymorphisms affect the light-chain region
of the cathepsin C protein, which is important in the tet-
ramerization of the matured cathepsin C protein. Their
eventual pathogenic role should be confirmed or excluded
by further studies. It is also possible that these polymor-
phisms share a common haplotype and are markers of
50%
25%
23%
44%
22%
16%
11%
5%
Homozygous missense mutaƟons
Homozygous nonsense mutaƟons
Homozygous frameshiŌ mutaƟons
Other types
One missense and one nonsense mutaƟon
One missense and one frameshiŌ mutaƟon
One nonsense and one frameshiŌ mutaƟon
Two missense mutaƟons 
Two nonsense mutaƟons
Other combinaƟons 
(A) (B)
Figure 2. The frequency of mutation types reported for PLS patients in (A) homozygous and (B) compound heterozygous forms.
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other underlying, still uncharacterized, genetic abnormali-
ties in these PLS patients.
Nonsense Variants
Nonsense mutations account for 23% (n = 17) of the
pathogenic mutations identified for the CTSC gene to
date. Nonsense mutations occur in all coding regions of
the gene; however, the majority is located in exons 5–7,
encoding the heavy-chain region of the cathepsin C pro-
tein (Fig. 3B), which is thought to be important for
enzyme activity (Turk et al. 2001).
Frameshift Variants
After missense and nonsense mutations, frameshift muta-
tions of the CTSC gene are the most common, account-
ing for 17% (n = 13) of the mutations identified to date.
Frameshift mutations occur in all coding regions of the
gene; however, the majority is located in exons 4–5
encoding the propeptide region of the cathepsin C pro-
tein (Fig. 3C). These mutations might influence the cleav-
age and the activation processes of the precursor
cathepsin C (Turk et al. 2001).
Other Deletions
Two in-frame deletions have been reported in PLS patients.
The c.199delTACCTTCAGAAGCTGGATACAGCA dele-
tion corresponding to p.Tyr67_Tyr75del was detected in
compound heterozygous form in combination with the
c.458C>T missense variant corresponding to p.Thr153Ile
(Hart et al. 2000a). This missense mutation is a common
polymorphism with no pathogenic role, as determined in
subsequent studies (Allende et al. 2001; Nakano et al.
2001; de Haar et al. 2004; Romero-Quintana et al. 2013).
The c.1213delCAT p.His405del in-frame deletion was
reported in homozygous form in an Indian PLS patient
(Wani et al. 2006). A large intragenic deletion of exons 3–7
was observed for another PLS patient in compound hetero-
zygous form, in combination with another missense muta-
tion, c.1156G>C p.Gly386Arg (Jouary et al. 2008).
Splicing Variant
To date, only one pathogenic splice-site mutation has
been reported for the CTSC gene (Toomes et al. 1999).
This single-nucleotide change occurs at the splice-accep-
tor site (5′ end of exon 3) c.485-1G>A (c.IVS3-1G>A).
UTR Variant
Only one pathogenic mutation has been identified in an
UTR of the CTSC gene: a single-nucleotide change c.-
55C>A at the 5′ end (Kosem et al. 2012). The mutation
results in complete loss of CTSC mRNA expression and
cathepsin C activity (Kosem et al. 2012). In silico analysis
suggested that the mutation disrupts the binding sites for
AP-2 and Sp transcription factors.
Compound Heterozygous Mutations
To date, 32% (n = 23) of all identified CTSC mutations
(n = 75) were detected in a compound heterozygous
Exclusion domain
Signal pepƟde
PropepƟde
Heavy chain
Light chain
FrameshiŌ mutaƟons
Missense mutaƟons 
Nonsense mutaƟons
(A)
(B)
(C)
Figure 3. Distribution of mutations on the cathepsin C protein: (A) missense, (B) nonsense, and (C) frameshift.
6 ª 2014 The Authors. Molecular Genetics & Genomic Medicine published by Wiley Periodicals, Inc.
CTSC and Papillon–Lefevre Syndrome N. Nagy et al.
form. The most frequent (44%, n = 10) compound het-
erozygotes involved two heterozygous missense mutations.
The combination of a heterozygous missense and a het-
erozygous nonsense mutation occurred in 22% (n = 5) of
the cases, a heterozygous missense and a heterozygous
frameshift mutation in 16% (n = 4), a heterozygous non-
sense and a heterozygous frameshift mutation in 11%
(n = 3), and two heterozygous nonsense mutations in 5%
(n = 1) (Fig. 2B).
Ethnic Variation
PLS has been reported in a diverse range of ethnic groups
from all over the world. A quarter (25%, n = 19) of the
mutations have been reported twice or more in different
ethnic groups. One of the most frequently reported mis-
sense mutation, the c.815G>Cp.Arg272Pro variant, has
been detected in Lebanese, Turkish, Saudi, Holland, Rus-
sian and French PLS patients (Toomes et al. 1999; Lefevre
et al. 2001; Zhang et al. 2002; de Haar et al. 2004; Pham
et al. 2004a,b; Noack et al. 2008a,b), while another fre-
quent nonsense mutation, c.96T>Gp.Tyr32X, has been
observed in PLS patients from Mexico and France
(Lefevre et al. 2001; Zhang et al. 2002; Pham et al. 2004a,
b). Moreover, a common frameshift mutation, c.566del-
CATACAT p.Thr189fsX200, has been found in Hungarian
and Moroccan PLS patients (Noack et al. 2008a,b; Farkas
et al. 2013).
Haplotype analyses of different PLS cases carrying iden-
tical mutations revealed that these relatively frequent
mutations resulted from independent founder events.
Two Turkish families carrying the same homozygous
nonsense mutation (c.856C>T p.Gln286X exhibited differ-
ent haplotypes, suggesting that the same mutation arose
in the two families independently (Hart et al. 1998,
2000a).
Biological Relevance
Cathepsin C is a lysosomal cysteine protease that was
first characterized as an activator of serine proteases
from immune and inflammatory cells (Turk et al. 2001).
Cell lines derived from cathepsin C-deficient mice fail to
activate groups of serine proteases. Unprocessed prote-
ases zymogens included granzymes A, B, and C, cathep-
sin G, neutrophil elastase, and chymase (Adkison et al.
2002).
The encoded cathepsin C precursor contains 463 amino
acids and includes a signal peptide (24 amino acids), an
exclusion domain (110 amino acids), a propeptide (96
amino acids), as well as heavy-(164 amino acids) and
light-(69 amino acids) chain regions (Turk et al. 2001;
Hewitt et al. 2004a,b). Precursor cathepsin C is processed
into the mature form by at least four cleavages of the
polypeptide (Turk et al. 2001; Adkison et al. 2002). The
signal peptide is removed during translocation or secre-
tion of the protein (Turk et al. 2001; Adkison et al.
2002). The exclusion domain is retained in the mature
enzyme and separated from the heavy and light chains by
excision of a minor C-terminal portion of the propeptide
region. The heavy and light chains are also generated by
cleavage (Turk et al. 2001; Adkison et al. 2002).
According to a BLAST (http://blast.ncbi.nlm.nih.gov/)
search, the cathepsin C protein is highly conserved in ver-
tebrates: the human cathepsin C shows 82% sequence
similarity with the sequence from dog, 70% with turkey,
and 63% with frog and zebrafish (Fig. 4). The most
highly conserved regions are the heavy chain, the light
chain, and the C-terminal portion of the exclusion
domain, which is thought to be important for enzyme
activity.
Half (53%, n = 40) of all CTSC gene mutations affect
the heavy-chain domain and result in different position-
ing of its N-terminus. As the N-terminal region is
involved in oligomer contacts with the N-terminal region
of the light chain, the mutation may interfere with tetra-
mer formation (Turk et al. 2001). This finding indicates
that tetramerization of the cathepsin C enzyme is crucial
for its function. The majority of the two most common
types of CTSC mutations (missense and nonsense) affect
this domain (Fig. 3A and B).
Sixteen percent (n = 12) of all CTSC mutations affect
the exclusion domain, which blocks access to the active
site and prevents substrates from binding any part except
their N-termini. Thirteen mutations were detected in the
exclusion domain; of these, six are nonsense variants, four
are missense mutations, and three are deletions (two
resulting in frameshift and one in an in-frame deletion).
Thirteen percent (n = 10) of all CTSC gene mutations
affect the propeptide fragment, which plays a pivotal role
in the activation of the cathepsin C precursor. The major-
ity of frameshift mutations are located in this domain
(Fig. 3C).
Twelve percent (n = 9) of all mutations affect the light-
chain domain, which is important for tetramerization of
the mature enzyme: four are missense mutations, two are
nonsense variants and one is an in-frame deletion. Three
common missense variants, rs151269219, rs28937571, and
rs3888798 are also located in this domain (Nakano et al.
2001; Hewitt et al. 2004a,b; de Haar et al. 2005; Noack
et al. 2008a,b).
Three percent (n = 3) of all mutations are located in
the signal peptide region, presumably affecting the trans-
location or secretion of the protein: one nonsense muta-
tion and one frameshift variant (Lefevre et al. 2001;
Hewitt et al. 2004a,b; Kurban et al. 2010).
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Clinical and Diagnostic Relevance
Historically, PLS was initially considered a variant of Mal
de Meleda, due to the similarity of the skin lesions. Sub-
sequently, the two diseases were determined to be differ-
ent forms of palmoplantar keratodermas (Gorlin et al.
1964). In addition to palmoplantar hyperkeratosis, peri-
odontal inflammation is a main feature of PLS. Clinical
diagnosis of HMS, an allelic variant of PLS, is based on
the presence of arachnodactly, acroosteolysis, pesplanus,
and onychogryposis in addition to palmoplantar hyper-
keratosis and periodontal inflammation (Hart et al.
2000b). AP1, which can be also considered a variable
expression of the PLS phenotype, is characterized by peri-
odontal inflammation and the lack of other symptoms.
All the three entities develop as a consequence of CTSC
mutations. Identification of a CTSC mutation gives a def-
inite diagnosis of PLS, HMS, or AP1 depending on the
presented clinical symptoms. In contrast, the absence of
CTSC mutation suggests a diagnosis of another palmopl-
antar keratoderma or nonsyndromic tooth abnormality.
Analysis of data reported for Hungarian PLS patients
revealed 75 CTSC gene mutations. The most frequent
mutations are recurrent and are reported both as homo-
zygous and as compound heterozygous. The identification
of the most frequent CTSC mutations has great clinical
significance, as they highlight regions of the gene that are
important for the development of the disease. The most
frequent mutations of the CTSC gene and their most
common associations are summarized in Table 2.
Approximately half 53% (n = 40) of the all 75 mutations
are located within exons 5–7, encoding the heavy-chain
region of the cathepsin C protein. Three types mutations
accounted for 93% (n = 61) of CTSC gene mutations:
missense 53% (n = 41), nonsense 23% (n = 17), and
frameshift 17% (n = 13). In addition, the majority of
missense, nonsense, and frameshift mutations occur in
exons 5–7.
Figure 4. Conservation of cathepsin C protein sequence in vertebrates.
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Genotype–Phenotype Correlations
In general, no strict genotype–phenotype correlations
have been identified for PLS. Analysis of CTSC mutation
location (i.e., within or outside the coding regions)
suggested that mutations located outside coding regions
are more likely to be associated with transgression of
the lesions (Hart et al. 2000a), although this hypothesis
has not been confirmed (Selvaraju et al. 2003; de Haar
et al. 2004; Hewitt et al. 2004a,b). It was also suggested
that CTSC gene mutations with little functional conse-
quences are putative causes of more common types of
early-onset periodontal disease (Hart et al. 2000c), but
this observation has also not been confirmed (Hewitt
et al. 2004a,b).
Mutations in the CTSC gene can lead to the devel-
opment of HMS or AP1 as well as PLS. The common
characteristic of these three entities is periodontal
inflammation (Hart et al. 2000b; Hewitt et al. 2004a,b;
Cury et al. 2005). While all three diseases involve tooth
abnormalities, PLS and HMS also involve characteristic
skin symptoms of palmoplantar hyperkeratosis (Hart
et al. 2000b; Hewitt et al. 2004a,b; Cury et al. 2005).
HMS is further characterized by arachnodactly, acroos-
teolysis, pesplanus, and onychogryphosis (Hart et al.
2000b; Hewitt et al. 2004a,b; Cury et al. 2005).
Several reports indicate that identical mutations of
the CTSC gene can give rise to multiple different phe-
notypes: the c.1040A>G p.Tyr347Cys missense mutation
can lead either PLS or AP1 (Toomes et al. 1999; Hart
et al. 2000c; Hewitt et al. 2004a,b) and the c.145C>T
p.Gln49X nonsense mutation results either in HMS or
PLS (Selvaraju et al. 2003; Rai et al. 2010). Hart et al.
(2000b) reported that the c.857A>G p.Gln286Arg mis-
sense mutation can also contribute to the development
of HMS and PLS (Hart et al. 2000b) (Fig. 1). Variable
expression of the phenotype associated with the CTSC
mutation may reflect the influence of other genetic
and/or environmental factors (Hart et al. 2000a).
Future Prospects
To date, the comparison of CTSC gene mutations has not
yet resulted in the identification of genotype–phenotype
correlations. Future efforts might provide insight into
these correlations and elucidate the mechanism of the dif-
ferent phenotypic variants – PLS, HMS, and AP1 – of the
disease. We believe that, to improve molecular analysis of
the CTSC gene, it is necessary to promote both better
awareness of the PLS, HMS, and AP1 phenotypic variants
of the same disease and better understanding of the
underlying molecular mechanisms. The availability of the
extended clinical findings from CTSC mutation carriers,
as provided by the CTSCbase, is critical for furthering
both our understanding of the disease and the develop-
ment of causative therapies that will be more specific and
effective than the symptomatic treatments currently avail-
able for patients with PLS, HMS, and AP1 variants.
Acknowledgments
This study was supported by the Hungarian TAMOP-
4.2.2.A-11/1/KONV-2012-0035, TAMOP-4.2.2/B-10/1/
KONV-2010-0012, TAMOP-4.2.4.A/2-11-1-2012-0001,
and TAMOP-4.2.2.A3 grants. Nikoletta Nagy is supported
by the Hungarian Scientific Research Foundation (OTKA)
PD104782 2012-2015 grant and Magyary Zoltan Postdoc-
toral Fellowship 2013-2014.
Table 2. The most frequent compound heterozygous pathogenic combinations of CTSC mutations.
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